Evidence map›Paper›PMID 41085781›Full record

SynthesisJournal of neuro-oncology2025

Hypofractionated vs. conventional fractionated radiotherapy in the temozolomide era for elderly patients with glioblastoma: a systematic review and meta-analysis by the Korean society for neuro-oncology.

Eunji Kim, Hye In Lee, Tae Hoon Roh, Young Zoon Kim, Do Hoon Lim, Se Jin Cho, Kihwan Hwang, Chan Woo Wee

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eunji Kim *Department of Radiation Oncology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea.
Hye In Lee *Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Tae Hoon RohDepartment of Neurosurgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Young Zoon KimDepartment of Neurosurgery, Center for Cerebrovascular Disease, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea.
Do Hoon LimDepartment of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Se Jin ChoDepartment of Radiology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, Republic of Korea. sejinchorad@gmail.com.
Kihwan HwangDepartment of Neurosurgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, Republic of Korea. coolghh@gmail.com.
Chan Woo WeeDepartment of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea. wcw0108@hanmail.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRadiotherapy (RT) is a cornerstone in GBM management, but the optimal RT regimen for elderly patients remains controversial. To compare survival outcomes of hypofractionated radiotherapy (HFRT) and conventional fractionated radiotherapy (CFRT) in elderly glioblastoma (GBM) patients through a systematic review and meta-analysis.

methodsA comprehensive search was conducted with Embase, Ovid-Medline, and Cochrane library databases. The hazard ratios (HRs) for overall survival (OS) were pooled using a random-effects model. Subgroup analyses were performed based on treatment modalities, prognostic factors, and age cut-offs.

resultsNine studies, including 2 prospective randomized trial, comprising 1,441 patients were included. The pooled analysis indicated no statistically significant difference in OS between HFRT and CFRT (HR 0.80; 95% confidence interval [CI]: 0.62-1.04). Subgroup analyses revealed that CFRT demonstrated a survival advantage in patients receiving concurrent chemoradiotherapy with temozolomide (TMZ) (HR 0.68; 95% CI: 0.49-0.93). Regardless of the age cut-off of 65 or 70 years, no significant differences were observed between two regimens.

conclusionsHFRT and CFRT provide comparable survival outcomes, but CFRT may offer significant survival benefits in specific subgroups, when combined with TMZ or adjusted for prognostic factors. HFRT remains a practical alternative for elderly or frail patients, highlighting the need for individualized RT strategies.

Indexed as

Antineoplastic Agents, AlkylatingBrain NeoplasmsDacarbazineDose Fractionation, RadiationGlioblastomaRadiation Dose HypofractionationAgedHumansRepublic of KoreaTemozolomideAntineoplastic Agents, AlkylatingDacarbazineTemozolomideElderly patientsGlioblastomaHypofractionationMeta-analysisRadiotherapy

Identifiers

PMID41085781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.